{"id":"insulin-diluent","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, facilitating glucose transport into muscle, fat, and liver cells. This lowers blood glucose levels and promotes anabolic metabolism. The diluent is a sterile solution used to reconstitute or dilute insulin formulations for injection.","oneSentence":"Insulin replaces or supplements the body's natural insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:22.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when oral agents are insufficient)"}]},"trialDetails":[{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT05081219","phase":"PHASE2","title":"SNIFF - Combo INI+EMPA Trial","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-09-14","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease","enrollment":47},{"nctId":"NCT05006599","phase":"PHASE2","title":"SNIFF - 3-Week Aptar CPS Device","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2025-05","conditions":"Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset","enrollment":""},{"nctId":"NCT02496780","phase":"PHASE2, PHASE3","title":"The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":65},{"nctId":"NCT06180824","phase":"NA","title":"Efficacy and Safety Between Different Dilution of Insulin","status":"RECRUITING","sponsor":"Universiti Sains Malaysia","startDate":"2024-01-09","conditions":"Hyperglycemia","enrollment":74},{"nctId":"NCT06144255","phase":"PHASE1","title":"Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)","status":"COMPLETED","sponsor":"Florian Schmitzberger","startDate":"2023-11-17","conditions":"Healthy","enrollment":6},{"nctId":"NCT03915613","phase":"PHASE1, PHASE2","title":"Brain Insulin Resistance in Mood Disorders","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-10-06","conditions":"Major Depressive Disorder, Bipolar Disorder, Anhedonia","enrollment":150},{"nctId":"NCT05067270","phase":"PHASE1","title":"A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-10-22","conditions":"Type 1 Diabetes Mellitus","enrollment":40},{"nctId":"NCT02988401","phase":"PHASE1, PHASE2","title":"Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-12-01","conditions":"Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive","enrollment":105},{"nctId":"NCT03383822","phase":"PHASE1, PHASE2","title":"Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2015-09-08","conditions":"Insulin Resistance","enrollment":7},{"nctId":"NCT02382536","phase":"","title":"Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults","status":"COMPLETED","sponsor":"Becton, Dickinson and Company","startDate":"2014-08","conditions":"Diabetes","enrollment":60},{"nctId":"NCT02810015","phase":"PHASE2","title":"Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study","status":"UNKNOWN","sponsor":"University of Manitoba","startDate":"2016-07","conditions":"Temporo-Myofascial Disorder","enrollment":40},{"nctId":"NCT02131948","phase":"PHASE1","title":"Regulation of Endogenous Glucose Production by Brain Insulin Action","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-11","conditions":"Insulin Resistance, Diabetes","enrollment":8},{"nctId":"NCT00570050","phase":"PHASE3","title":"Effect of Intranasal Insulin on Depressive Symptoms in Major Depressive Disorder","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-06","conditions":"Major Depressive Disorder","enrollment":35},{"nctId":"NCT00673621","phase":"PHASE1","title":"A Study Designed to Determine if the Pharmacokinetic Disposition of Inhaled Insulin Exposure is the Same for Asthmatics and Non-asthmatics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2008-05","conditions":"Asthma, Diabetes Mellitus","enrollment":30},{"nctId":"NCT00314314","phase":"PHASE3","title":"The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2006-05","conditions":"Bipolar Disorder","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin / Diluent","genericName":"Insulin / Diluent","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin is a protein that acts as an agonist to the insulin receptor, a protein modality. It is used to treat various conditions, including Major Depressive Disorder, Cystic Fibrosis, and Multiple Sclerosis, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}